Trial · NCT03453840
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| AUC0-21d | HIV-infected 3-day AL Intensive PK | 144 | 95% Confidence Interval 114 to 182 | hr*ug/mL | |
| AUC0-21d | HIV-infected 5-day AL Intensive PK | 205 | 95% Confidence Interval 151 to 279 | hr*ug/mL | |
| AUC0-21d | HIV-uninfected 3-day AL Intensive PK | 259 | 95% Confidence Interval 222 to 302 | hr*ug/mL | |
| AUC0-21d | HIV-uninfected 5-day AL Intensive PK | 318 | 95% Confidence Interval 274 to 370 | hr*ug/mL | |
| Recurrent Parasitemia Following Treatment by Day 42 (Recrudescence or New Infection) | HIV-infected 3-day AL | 19 | Participants | ||
| Recurrent Parasitemia Following Treatment by Day 42 (Recrudescence or New Infection) | HIV-infected 5-day AL | 18 | Participants | ||
| Recurrent Parasitemia Following Treatment by Day 42 (Recrudescence or New Infection) | HIV-uninfected 3-day AL | 80 | Participants | ||
| Recurrent Parasitemia Following Treatment by Day 42 (Recrudescence or New Infection) | HIV-uninfected 5-day AL | 66 | Participants | ||
| AUC0-8h for Artemether | HIV-infected 3-day AL Intensive PK | 64.0 | 95% Confidence Interval 45.5 to 90 | hr*ng/mL | |
| AUC0-8h for Artemether | HIV-infected 5-day AL Intensive PK | 71.7 | 95% Confidence Interval 54.8 to 93.8 | hr*ng/mL | |
| AUC0-8h for Artemether | HIV-uninfected 3-day AL Intensive PK | 95.8 | 95% Confidence Interval 77.5 to 118 | hr*ng/mL | |
| AUC0-8h for Artemether | HIV-uninfected 5-day AL Intensive PK | 78.6 | 95% Confidence Interval 61.3 to 101 | hr*ng/mL | |
| AUC0-8h for Dihydroartemisinin | HIV-infected 3-day AL Intensive PK | 109 | 95% Confidence Interval 83.9 to 142 | hr.ng/mL | |
| AUC0-8h for Dihydroartemisinin | HIV-infected 5-day AL Intensive PK | 95.8 | 95% Confidence Interval 69.7 to 132 | hr.ng/mL | |
| AUC0-8h for Dihydroartemisinin | HIV-uninfected 3-day AL Intensive PK | 241 | 95% Confidence Interval 216 to 269 | hr.ng/mL | |
| AUC0-8h for Dihydroartemisinin | HIV-uninfected 5-day AL Intensive PK | 229 | 95% Confidence Interval 202 to 261 | hr.ng/mL | |
| Cmax for Lumefantrine | HIV-infected 3-day AL Intensive PK | 5065 | 95% Confidence Interval 3894 to 6589 | ng/mL | |
| Cmax for Lumefantrine | HIV-infected 5-day AL Intensive PK | 6027 | 95% Confidence Interval 4253 to 8543 | ng/mL | |
| Cmax for Lumefantrine | HIV-uninfected 3-day AL Intensive PK | 7236 | 95% Confidence Interval 6023 to 8692 | ng/mL | |
| Cmax for Lumefantrine | HIV-uninfected 5-day AL Intensive PK | 8450 | 95% Confidence Interval 7085 to 10079 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03453840/results